Clinical trials recruiting for Alzheimer's disease

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 80 locations
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 150 locations
• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
  NCT07094516 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 74 locations
• A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
  NCT05452031 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
  NCT06403345 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
  NCT06297590 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 10 locations
• A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease
  NCT06837272 · Phase: Not specified · Ages: 60 Years to 80 Years · Sex: All (male and female) · 1 location
• A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
  NCT06411561 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China
  NCT05886114 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years to 80 Years · Sex: All (male and female) · 1 location
• A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
  NCT06668610 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 85 Years · Sex: All (male and female) · 1 location
• A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931
  NCT05730023 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · 4 locations
• A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants
  NCT06786676 · Phase: Phase 1 · Ages: 19 Years to 85 Years · Sex: All (male and female) · 1 location
• A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
  NCT07230652 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
  NCT06745583 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 2 locations
• A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
  NCT06702124 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 144 locations
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 159 locations
• A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
  NCT07580703 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
  NCT06322667 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
  NCT06810960 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD
  NCT05081596 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
  NCT06566170 · Phase: Not specified · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
  NCT05877196 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• A Study of AMDX-2011P in Participants With Alzheimer's Disease
  NCT06514001 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
  NCT06619613 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 59 locations
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · 72 locations
• A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
  NCT06996730 · Phase: Phase 2, Phase 3 · Ages: 25 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of LY3439539 in Participants With Alzheimer's Disease
  NCT07598370 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 11 locations
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
  NCT06657768 · Phase: Phase 1 · Ages: 45 Years to 85 Years · Sex: All (male and female) · 13 locations
• A Study of NTRX-07 in Participants With Alzheimer's Disease
  NCT07058688 · Phase: Phase 2 · Ages: 65 Years to 80 Years · Sex: All (male and female) · 6 locations
• A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
  NCT06057909 · Phase: Not specified · Ages: 50 Years to 95 Years · Sex: All (male and female) · 1 location
• A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
  NCT06803823 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 38 locations
• A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
  NCT05413655 · Phase: Phase 2 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• A Study of Psychedelics in Healthy Older Adults With Low Well-being
  NCT07386730 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.
  NCT07059871 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 90 Years · Sex: All (male and female) · 1 location
• A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  NCT07717411 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 7 locations
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 143 locations
• A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
  NCT07633470 · Phase: Phase 4 · Ages: 50 Years and older · Sex: All (male and female) · 14 locations
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
  NCT05511363 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 129 locations
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 154 locations
• A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
  NCT06995573 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 10 locations
• A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
  NCT05462106 · Phase: Phase 1, Phase 2 · Ages: 35 Years to 85 Years · Sex: All (male and female) · 26 locations
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
  NCT06651567 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · 70 locations
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
  NCT06540833 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · 67 locations
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 110 locations
• A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
  NCT07599670 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 12 locations
• A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
  NCT07214727 · Phase: Phase 1 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 13 locations
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 293 locations
• A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
  NCT07636811 · Phase: Phase 2 · Ages: 40 Years to 55 Years · Sex: All (male and female) · 3 locations
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 44 locations
• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
  NCT07502560 · Phase: Phase 4 · Ages: 76 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · 119 locations
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · 127 locations
• A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
  NCT07252440 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 252 locations
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
  NCT05231785 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
  NCT07758595 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
  NCT07328451 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
  NCT07688213 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · 1 location
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
  NCT07234942 · Phase: Phase 1 · Ages: 50 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
  NCT06372821 · Phase: Phase 1 · Ages: 21 Years to 80 Years · Sex: All (male and female) · 2 locations
• A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.
  NCT07218081 · Phase: Phase 1 · Ages: 65 Years to 85 Years · Sex: All (male and female) · 1 location
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female) · 149 locations
• ADRC Clinical Cohort (Alzheimer's Disease)
  NCT06703541 · Phase: Not specified · Ages: 25 Years to 80 Years · Sex: All (male and female) · 1 location
• AI App for Management of Atopic Dermatitis
  NCT06362629 · Phase: Not applicable (e.g. observational or device study) · Ages: 1 Year to 75 Years · Sex: All (male and female) · 1 location
• ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
  NCT07392723 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness
  NCT07679906 · Phase: Not specified · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
  NCT07158905 · Phase: Phase 1 · Ages: 65 Years to 80 Years · Sex: All (male and female) · 6 locations
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 104 locations
• Adapting RDAD for DS
  NCT07425769 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Advances in Telephone-based Cognitive Screening Procedures
  NCT06337578 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms
  NCT06801639 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years to 85 Years · Sex: All (male and female) · 1 location
• Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）
  NCT06669182 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 85 Years · Sex: All (male and female) · 4 locations
• Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias
  NCT03035851 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
  NCT07367815 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• Alzheimer Prevention Trials (APT) Webstudy
  NCT03638583 · Phase: Not specified · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• Alzheimer"s Imaging Biomarkers in Obesity
  NCT05077579 · Phase: Not specified · Ages: 40 Years to 60 Years · Sex: All (male and female) · 1 location
• Alzheimer's Disease Genetics Study
  NCT00064870 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
  NCT07089303 · Phase: Not specified · Ages: 55 Years to 90 Years · Sex: All (male and female) · 1 location
• Alzheimer's Disease Treated With Vagus Nerve Stimulation
  NCT06923007 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
  NCT03657745 · Phase: Not specified · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study
  NCT07332260 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
  NCT06170268 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
  NCT02022943 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · 1 location
• Alzheimer's Tau Platform: Master Protocol
  NCT06957418 · Phase: Phase 2 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 3 locations
• Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
  NCT07099053 · Phase: Not specified · Ages: 55 Years to 110 Years · Sex: All (male and female) · 1 location
• Amyloid-β Clearance Mechanisms in Alzheimer's Disease
  NCT05059158 · Phase: Not specified · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
  NCT05908695 · Phase: Phase 4 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 50 locations
• An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
  NCT07724132 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 2 locations
• An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease
  NCT06852352 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female) · 2 locations
• An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
  NCT07153848 · Phase: Not specified · Ages: 45 Years to 85 Years · Sex: All (male and female) · 2 locations
• An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
  NCT07764146 · Phase: Phase 1 · Ages: 30 Years to 80 Years · Sex: All (male and female) · 1 location
• Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
  NCT07115238 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
  NCT06788119 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
  NCT05748613 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female) · 6 locations
• Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases
  NCT06295263 · Phase: Not specified · Ages: 8 Years to 100 Years · Sex: All (male and female) · 1 location
• Assess Fibrin in Brains With AD/ADRD
  NCT05336695 · Phase: Phase 1, Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Alzheimer's disease often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Alzheimer's disease trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.